—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Amgen Inc (AMGN) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for AMGN, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-10-06

DayWeekMonth3 months
AMGN−0.1%−5.0%−7.9%+9.4%
Longevity & Healthspan−1.9%−3.5%−4.0%—
HALO Growth 100+0.5%+0.7%−4.9%—

Against the index: 5.7 pts behind on the week, 3.0 pts behind on the month; against its Longevity & Healthspan sleeve 3.9 pts behind on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Mentioned on Closelooknet 1 piece · newest: Morning 10, “Oil knocks on $100 and Wall Street sells everything but the AI pipe: Intel +9%, Lumentum +11%, Dow −1.2% — Seoul buys the dip and the Kospi is back above 7,000” (2026-09-09)

Mentioned on Closelooknet

Where AMGN appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in US: −2.1% week · −2.2% month · +3.3% quarter · +16.4% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.40 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How AMGN has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.40 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Amgen Inc moved 0.40% on average · correlation 0.13 · higher than 40% of US names
  • Beta, last 3 months 0.77 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.86% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.01% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against AMGN on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Amgen Inc

AMGN in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Amgen discovers, develops and manufactures human therapeutics, with products spanning rheumatoid arthritis, osteoporosis, cardiovascular risk reduction and rare diseases such as Enbrel, Prolia and Repatha. It sells through pharmaceutical wholesale distributors to hospitals, clinics and pharmacies worldwide. It is headquartered in Thousand Oaks, California.
Where it sits in the stack
Amgen sits in our HALO Growth 100 index, in the Longevity & Healthspan sleeve, which groups GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders. Within that sleeve it functions as a broad-portfolio compounder, supplying chronic-disease treatments to a demand curve set by an ageing population rather than a single therapeutic bet.
Who it is priced against
Closelooknet's peer group places it with Eli Lilly, Regeneron, Zealand Pharma, Vertex, Illumina, Novo Nordisk, Natera and Gerresheimer, on the reasoning that demographics drives demand across the group; the market also compares it with Pfizer.
Why Closelooknet tracks it
Amgen holds a seat in our HALO Growth 100, and also sits in the Nasdaq-100 and the Dow Jones Industrial Average. It carries a Closelooknet score, strongest on the quality module and weakest on valuation. The Morning 10 has quoted it once, noting a sharp single-day drop during a broader Wall Street sell-off.
What the diary watches
The diary watches whether the valuation module stays the weak point as the quality score holds, and whether the recent downgrade to Hold from Buy marks a shift in how the market reads the stock.

Amgen Inc (AMGN) trades on US exchanges, classified under Healthcare. Constituent of HALO Growth 100.

The Closelooknet company score reads 55/100 composite (momentum 72, quality 86, valuation 41) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: AMGN news on the tape · index compare · sector dispersion · scanner.

The Street on this name 7 analyst actions on the wire · latest: price target by Scotiabank, 2026-09-28

The Street on this name

Analyst actions and the latest print for AMGN from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Scotiabank — target 500 from 450 Target raised to $500 from $450 (+19.7% to spot) 2026-09-28
  • Price target Jefferies — target 410 Target set to $410 (-0.1% to spot) 2026-09-23
  • Price target Piper Sandler — target 457 from 427 Target raised to $457 from $427 (+3.3% to spot) 2026-08-20

7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 2.47%, quarterly · last 2.52 USD on 2026-08-21

Dividends and capital return

What AMGN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 9.94 USD per share · a 2.47% yield on the 2026-10-06 close 4 distributions, paid quarterly 2026-10-06
  • Change on the year +5.9% against the prior twelve months prior twelve months 9.39 USD per share
  • Last distribution 2.52 USD per share as the price series records it, within days of the ex-date 2026-08-21
  • By calendar year 2023: 2.13 USD (partial) · 2024: 9.00 USD · 2025: 9.52 USD · 2026: 7.56 USD to date first distribution recorded in the three-year window: 2023-11-16
  • Dividends paid, FY2025 5.12 bn USD 44% of earnings
  • Buybacks, FY2025 none reported
  • Share count +0.2% in FY2025 494 m USD of stock-based compensation in the year
  • Capital returned 5.12 bn USD · 63% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Amgen Inc (AMGN)?

Amgen Inc trades as AMGN on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is AMGN in a Closelooknet index?

Yes — Amgen Inc is a constituent of HALO Growth 100, as of 2026-10-07.

What is Amgen Inc's Closelooknet composite score?

55 out of 100, with momentum 72, quality 86 and valuation 41 sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does AMGN trade against its moving averages?

Stochastic turned down: Its stochastic crossed down from overbought (%K 57.5 under %D 70.2) 3 sessions ago — momentum is cooling. As of 2026-10-05 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is AMGN doing against its Closelooknet index?

Over the past month Amgen Inc is −7.9% against −4.9% for the HALO Growth 100 — 3.0 points behind its index, as of 2026-10-06. Its Longevity & Healthspan sleeve is −4.0% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Amgen Inc compare with its peers?

Against its peer group (HALO Growth 100 · Longevity & Healthspan), Amgen Inc (AMGN) sits 9.9% below its 52-week high, 1.6% below its 50-day average; Eli Lilly and Company (LLY) is 11.6% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Novo Nordisk A/S (NVO) is 39.3% below. Put any of them next to AMGN in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Amgen Inc trade when bond yields rise?

Over the past year Amgen Inc had a beta of 0.40 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 40% of US names. On the 10 sessions in which long bonds fell most it moved −0.86% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Amgen Inc?

Amgen Inc appears in 1 Closelooknet piece, most recently Morning 10: Oil knocks on $100 and Wall Street sells everything but the AI pipe: Intel +9%, Lumentum +11%, Dow −1.2% — Seoul buys the dip and the Kospi is back above 7,000 (2026-09-09). What Closelooknet said most recently: Wall Street came back from the long weekend and sold: the Dow lost 1.2%, the S&P 500 0.6%, the Nasdaq 0.3%, with Amgen −10% and Salesforce −4% doing the damage. (Morning 10, 2026-09-09). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Amgen Inc do?

Amgen discovers, develops and manufactures human therapeutics, with products spanning rheumatoid arthritis, osteoporosis, cardiovascular risk reduction and rare diseases such as Enbrel, Prolia and Repatha. It sells through pharmaceutical wholesale distributors to hospitals, clinics and pharmacies worldwide. It is headquartered in Thousand Oaks, California. Closelooknet's peer group places it with Eli Lilly, Regeneron, Zealand Pharma, Vertex, Illumina, Novo Nordisk, Natera and Gerresheimer, on the reasoning that demographics drives demand across the group; the market also compares it with Pfizer.

Where does Amgen Inc sit in the AI build-out?

Amgen sits in our HALO Growth 100 index, in the Longevity & Healthspan sleeve, which groups GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders. Within that sleeve it functions as a broad-portfolio compounder, supplying chronic-disease treatments to a demand curve set by an ageing population rather than a single therapeutic bet. Amgen holds a seat in our HALO Growth 100, and also sits in the Nasdaq-100 and the Dow Jones Industrial Average. It carries a Closelooknet score, strongest on the quality module and weakest on valuation. The Morning 10 has quoted it once, noting a sharp single-day drop during a broader Wall Street sell-off.

Does Amgen Inc pay a dividend?

Amgen Inc has paid 9.94 USD per share over the last twelve months, paid quarterly, a trailing yield of 2.47% on the 2026-10-06 close; the last distribution recorded in the price series was 2.52 USD on 2026-08-21. In fiscal 2025 the company paid 5.12 bn USD in dividends, 63% of that year’s free cash flow. The share count rose 0.2% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Amgen Inc recently?

The most recent analyst action on Amgen Inc on the Closelooknet wire is a price target by Scotiabank on 2026-09-28 (target 500 from 450). 7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for AMGN, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Drug Manufacturers - General. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.